Kidney Week

Abstract: FR-PO857

A Biomarker of Collagen Type VI Formation Is Associated to Allograft Outcome in Kidney Transplant Recipients

Session Information

• Transplantation: Basic
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 1801 Transplantation: Basic

Authors

• Genovese, Federica, Nordic Bioscience, Herlev, Denmark

Federica Genovese,

• Sparding, Nadja, Nordic Bioscience, Herlev, Denmark

Nadja Sparding,

• Rasmussen, Daniel Guldager Kring, Nordic Bioscience, Herlev, Denmark

Daniel Guldager Kring Rasmussen,

• Karsdal, Morten Asser, Nordic Bioscience, Herlev, Denmark

Morten Asser Karsdal,

• Birn, Henrik, Department of Biomedicine and Department of Nephrology, Aarhus C, Denmark

Henrik Birn,

• Jespersen, Bente, Aarhus Universityhospital, Aarhus N, Denmark

Bente Jespersen,

• Norregaard, Rikke, Aarhus University, AARHUS N, Denmark

Rikke Norregaard,

Background

A careful evaluation of kidney transplant recipients is important for a successful allograft outcome. Non-invasive biomarkers are needed to predict immediate and long-term kidney function after transplantation.
Preliminary findings have identified PRO-C6, a non-invasive biomarker of collagen type VI formation related to burden of kidney fibrosis, as a good prognostic marker for kidney function loss and mortality in chronic kidney disease patients.

Methods

Here we evaluate the prognostic potential of PRO-C6 in kidney transplant recipient by measuring PRO-C6 in plasma of 219 patients before transplantation, and 1 day, 3 months and 12 months after transplantation, by means of an ELISA developed at Nordic Bioscience.

Results

Levels of the serum PRO-C6 decreased significantly from baseline (median, 95% CI: 50.7, 46.7-53.5) to day 1 (median, 95% CI: 34.8, 31.1-38.3) and further decreased at month 3 (median, 95% CI: 14.2, 12.7-14.5), but not significantly from month 3 to month 12 (median, 95% CI: 13.5, 12.7-14.5).
PRO-C6 correlated with plasma creatinine before transplantation (rho =0.43, p<0.0001), 1 day after rho for PRO-C6 vs plasma creatinine was 0.67, p<0.0001, at 3 months after rho for PRO-C6 vs measured GFR was -0.58, p<0.0001, and at 12 months after rho for PRO-C6 vs measured GFR was -0.57, p<0.0001.
PRO-C6 measured either before transplantation and at day 1 after transplantation could identify patients who required dialysis one week after transplantation (delayed graft function) (AUC: 0.679, p<0.0001; and AUC: 0.860, p<0.0001, respectively). PRO-C6 measured 1 day after transplantation identified patients who still required dialysis three months after transplantation (AUC: 0.789, p<0.0001). Plasma creatinine measured one day after transplantation did not have any prognostic ability to identify patients with no graft function after 3 months.
PRO-C6 measured 1 day after transplantation was also associated to the time needed to reach a 50% reduction in plasma creatinine after transplantation (HR per doubling of PRO-C6: 0.659 (0.548-0.792), p<0.0001).

Conclusion

PRO-C6 measured in plasma was associated with delayed graft function and no function at 3 months after transplantation and it can potentially be used to identify the patients at risk of graft function loss.

Funding

• Commercial Support –